```html

Kallikrein‑Kinin Excess (Hereditary Angioedema)

What is Kallikrein‑kinin excess (hereditary angioedema)?

Hereditary angioedema (HAE) is a rare, genetic disorder caused by an over‑activity of the kallikrein‑kinin system, which leads to **excess production of bradykinin**—a peptide that makes blood vessels leaky. When bradykinin builds up, fluid moves into the deeper layers of the skin and mucosal tissues, producing sudden, painful swelling (angioedema). Unlike the more common histamine‑mediated allergic swelling, HAE does not respond to antihistamines or steroids and often lacks urticaria (hives).

HAE is usually inherited in an autosomal dominant pattern, meaning a child has a 50 % chance of inheriting the mutation if one parent is affected. The condition can present at any age, sometimes as early as infancy, and the severity varies widely between individuals.

Common Causes

While hereditary angioedema is genetic, several related conditions or triggers can produce a kallikrein‑kinin excess state. The most common causes include:

• HAE type I (C1‑INH deficiency): 85 % of cases; reduced production of functional C1‑esterase inhibitor (C1‑INH).
• HAE type II (C1‑INH dysfunction): 15 % of cases; normal amount but dysfunctional C1‑INH.
• HAE with normal C1‑INH (HAE‑nC1INH): Mutations in genes such as FXII, PLG, ANGPT1, KNG1 or MYOF cause excessive bradykinin despite normal C1‑INH levels.
• Acquired C1‑INH deficiency: Often associated with lymphoproliferative disorders or auto‑immune diseases (e.g., systemic lupus erythematosus).
• Bradykinin‑producing drugs: ACE inhibitors, neprilysin inhibitors, and DPP‑4 inhibitors can raise bradykinin levels, mimicking HAE.
• Trauma or surgery: Physical injury to tissues can trigger local kallikrein activation.
• Infections: Upper‑respiratory viral or bacterial infections can precipitate attacks.
• Hormonal fluctuations: Estrogen‑containing oral contraceptives, hormone replacement therapy, and pregnancy can worsen symptoms.
• Stress (emotional or physical): Stress hormones can amplify kallikrein activation.
• Dental procedures: Manipulation of oral tissues is a well‑documented trigger for facial or tongue swelling.

Associated Symptoms

Symptoms of HAE usually appear as episodic swelling that can last 2–5 days if untreated. Commonly affected sites and associated features include:

• Swelling of the face, lips, and periorbital area – often painless but can cause a feeling of tightness.
• Extremity edema – swelling of the arms or legs, sometimes limiting movement.
• Gastrointestinal attacks – abdominal pain, nausea, vomiting, and diarrhea due to bowel wall edema; may mimic an acute abdomen.
• Upper airway involvement – swelling of the tongue, larynx, or pharynx, which can cause speech changes, difficulty swallowing, or airway obstruction.
• Skin may feel “woody” rather than warm or itchy (distinguishing it from allergic angioedema).
• No itching, rash, or urticaria – a key clinical clue.

When to See a Doctor

Because HAE can rapidly become life‑threatening, especially with airway involvement, patients should seek medical attention promptly if they experience any of the following:

• Sudden swelling of the lips, tongue, throat, or face that progresses within hours.
• Difficulty breathing, shortness of breath, or a hoarse voice.
• Severe abdominal pain with vomiting or signs of intestinal obstruction.
• Swelling that does not improve with standard antihistamine or steroid therapy.
• Recurring episodes of unexplained angioedema, especially with a family history of similar attacks.

Even if symptoms seem mild, informing a healthcare professional is essential to obtain a proper diagnosis and to discuss preventive strategies.

Diagnosis

Diagnosing HAE requires a combination of clinical suspicion, family history, and laboratory testing.

1. Detailed medical history

• Age of onset, frequency, and typical triggers.
• Family members with similar swelling episodes.
• Response (or lack thereof) to antihistamines, steroids, or epinephrine.

2. Physical examination

• Document location and size of edema.
• Observe for abdominal tenderness or signs of airway compromise.

3. Laboratory tests

• C4 complement level: Usually low in HAE types I and II.
• C1‑esterase inhibitor (C1‑INH) antigenic level: Decreased in type I.
• C1‑INH functional assay: Decreased functional activity in type I and II.
• Genetic testing for SERPING1 (the gene encoding C1‑INH) and for the newer HAE‑nC1INH genes when C1‑INH studies are normal.

4. Additional investigations (when needed)

• CT or MRI of the neck to evaluate airway edema during an acute attack.
• Abdominal imaging (ultrasound/CT) if severe abdominal pain raises concern for complications such as intestinal obstruction.

Reference: Mayo Clinic; National Institute of Allergy and Infectious Diseases (NIAID) guidelines; WHO classification of rare diseases.

Treatment Options

Therapy for HAE is divided into three main goals: (1) abort an ongoing attack, (2) prevent future attacks, and (3) manage acute airway emergencies.

1. Acute attack management

• C1‑INH concentrate (plasma‑derived or recombinant): The first‑line agent. Doses are weight‑based (e.g., 20 U/kg) and can be administered intravenously or subcutaneously.
• Icatibant (Firazyr): A selective bradykinin‑B2 receptor antagonist given subcutaneously (30 mg) for rapid relief, especially for abdominal or facial attacks.
• Ecallantide (Kalbitor): A kallikrein inhibitor, administered subcutaneously (30 mg); useful when C1‑INH products are unavailable.
• Supportive care: oxygen, intravenous fluids, and airway protection (intubation or emergency cricothyrotomy) if airway swelling progresses.

2. Long‑term prophylaxis (LTP)

• Lanadelumab (Suliqua): A monoclonal antibody that inhibits plasma kallikrein, given subcutaneously every 2–4 weeks.
• Berotralstat (Orladeyo): An oral kallikrein inhibitor taken once daily.
• Regular C1‑INH replacement: Subcutaneous C1‑INH (e.g., Haegarda) administered 2–3 times weekly.
• Adjunctive measures: avoiding known triggers, careful use of estrogen‑containing medications, and stress‑management techniques.

3. Short‑term (on‑demand) prophylaxis

• Administer C1‑INH concentrate before high‑risk procedures (dental work, surgery, or strenuous exercise).
• Consider icatibant or ecallantide if a procedure is known to precipitate an attack and prior on‑demand therapy was effective.

4. Home care strategies

• Patients should be trained to self‑administer on‑demand therapy (C1‑INH, icatibant, or ecallantide) as soon as swelling begins.
• Maintain an up‑to‑date emergency action plan and carry a medical alert bracelet stating “Hereditary Angioedema – watch for airway swelling.”
• Keep a log of attacks, triggers, and response to treatments to help the care team adjust therapy.

Prevention Tips

While HAE cannot be cured, many attacks can be prevented with vigilant lifestyle choices and appropriate prophylactic medication.

• Identify personal triggers: Keep a diary of foods, stressors, medications, and activities that precede attacks.
• Avoid estrogen‑containing products: Choose non‑hormonal contraception or progesterone‑only formulations.
• Stay hydrated: Dehydration can increase blood viscosity and promote edema.
• Practice stress‑reduction techniques: Yoga, mindfulness, or counseling can lower catecholamine surges that may activate kallikrein.
• Schedule routine prophylaxis: Adhere to prescribed lanadelumab, berotralstat, or regular C1‑INH therapy.
• Inform healthcare providers: Ensure dentists, surgeons, and anesthesiologists know of the diagnosis and have a plan for peri‑procedural prophylaxis.
• Vaccinations: Maintain up‑to‑date immunizations (especially influenza and COVID‑19) to reduce infection‑related attacks.
• Carry rescue medication: Always have on‑hand a dose of C1‑INH concentrate or icatibant for rapid self‑administration.

Emergency Warning Signs

Key Takeaways

• Hereditary angioedema is a rare, genetic disorder caused by excess bradykinin due to a malfunctioning kallikrein‑kinin system.
• Swelling is typically non‑itchy, lasts days, and does not respond to antihistamines or steroids.
• Prompt diagnosis relies on low C4 levels and abnormal C1‑INH quantity or function; genetic testing is increasingly helpful.
• Effective treatments (C1‑INH concentrate, icatibant, ecallantide, lanadelumab, berotralstat) can abort attacks and prevent future episodes.
• Patients must have an emergency plan, carry rescue medication, and seek immediate care for any signs of airway compromise.

For personalized guidance, consult an allergist–immunologist or a specialized HAE clinic. Reliable information can also be found at the Mayo Clinic, the CDC, the NIH, and the WHO.

```